155 related articles for article (PubMed ID: 38901138)
21. Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics.
Alhazzani K; Almangour A; Alsalem A; Alqinyah M; Alhamed AS; Alhamami HN; Alanazi AZ
Diseases; 2023 Oct; 11(4):. PubMed ID: 37873791
[TBL] [Abstract][Full Text] [Related]
22. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
23. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
24. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors.
Haouala A; Rumpold H; Untergasser G; Buclin T; Ris HB; Widmer N; Decosterd LA
Drug Metab Lett; 2010 Apr; 4(2):114-9. PubMed ID: 20446917
[TBL] [Abstract][Full Text] [Related]
25. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
[No Abstract] [Full Text] [Related]
26. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
27. PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?
Deb S; Sjöström C; Tharmakulanathan A; Boknäs N; Lotfi K; Ramström S
Thromb Res; 2016 Apr; 140 Suppl 1():S196-7. PubMed ID: 27161743
[TBL] [Abstract][Full Text] [Related]
28. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
[TBL] [Abstract][Full Text] [Related]
30. Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma.
Yazdi MH; Faramarzi MA; Nikfar S; Abdollahi M
Biomed Pharmacother; 2017 Nov; 95():1556-1564. PubMed ID: 28950655
[TBL] [Abstract][Full Text] [Related]
31. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
32. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
33. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
[TBL] [Abstract][Full Text] [Related]
34. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.
Khoshnam-Rad N; Gheymati A; Jahangard-Rafsanjani Z
Anticancer Drugs; 2022 Jan; 33(1):e1-e8. PubMed ID: 34282745
[TBL] [Abstract][Full Text] [Related]
36. Treatments for chronic myeloid leukemia: a qualitative systematic review.
Ferdinand R; Mitchell SA; Batson S; Tumur I
J Blood Med; 2012; 3():51-76. PubMed ID: 22915985
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic immune monitoring of CD4
Lu Z; Xu N; Zhou X; Gao G; Li L; Huang J; Li Y; Lu Q; He B; Pan C; Liu X
Oncol Lett; 2017 Aug; 14(2):1363-1372. PubMed ID: 28808483
[TBL] [Abstract][Full Text] [Related]
38. The impact of vincristine on testicular development and function in childhood cancer.
Clark I; Brougham MFH; Spears N; Mitchell RT
Hum Reprod Update; 2023 Mar; 29(2):233-245. PubMed ID: 36495566
[TBL] [Abstract][Full Text] [Related]
39. High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review.
Gerritse SL; Janssen JBE; Labots M; de Vries R; Rudek M; Carducci M; van Erp NP; Verheul HMW
Cancer Treat Rev; 2021 Jun; 97():102171. PubMed ID: 33823432
[TBL] [Abstract][Full Text] [Related]
40. The adverse effects of psychotropic drugs as an endocrine disrupting chemicals on the hypothalamic-pituitary regulation in male.
Ilgin S
Life Sci; 2020 Jul; 253():117704. PubMed ID: 32339542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
